Literature DB >> 1102987

Multiple-myeloma bone disease. The comparative effect of sodium fluoride and calcium carbonate or placebo.

R A Kyle, J Jowsey, P J Kelly, D R Taves.   

Abstract

A randomized double-blind study was carried out in 26 patients with multiple myeloma to compare the therapeutic effect of sodium fluoride (50 mg twice daily) plus calcium carbonate (1 g four times daily) and placebo. All patients also received melphalan and prednisone for one week every six weeks. Bone biopsies for microradiography and histology, and videodensitometry as well as conventional roentgenograms, 99mTc-polyphosphate bone scans, and bone densitometry of the mid and distal radius, were done initially and one year after therapy. Microradiography and videodensitometry studies revealed significant increases in bone formation (P less than 0.01) and bone mass (P less than 0.005) in the fluoride-calcium group. Bone trabeculae appeared thickened on roentgenograms of six of 13 fluoride-calcium-treated patients (P less than 0.02). Technetium bone scans and bone densitometry determinations proved insensitive for detection of skeletal changes. Fluoride calcium should be considered a useful adjunct in the treatment for multiple myeloma.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1102987     DOI: 10.1056/NEJM197512252932602

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  13 in total

1.  Robert Arthur Kyle, MD: a conversation with the editor.

Authors:  Robert Arthur Kyle; William Clifford Roberts
Journal:  Proc (Bayl Univ Med Cent)       Date:  2010-10

2.  Controversies in the treatment of plasma cell myeloma.

Authors:  D E Bergsagel
Journal:  Postgrad Med J       Date:  1985-02       Impact factor: 2.401

3.  Human vertebral bone: relation of strength, porosity, and mineralization to fluoride content.

Authors:  I D Stein; G Granik
Journal:  Calcif Tissue Int       Date:  1980       Impact factor: 4.333

4.  [Enteral absorption of high calcium doses determined by means of stable isotopes (author's transl)].

Authors:  D Behne; P Brätter; U Herzfeld; D Kraft
Journal:  Klin Wochenschr       Date:  1978-01-15

5.  Quantitative measurement of fractional bone volume using digital scanning videodensitometry.

Authors:  R A Robb; J Jowsey
Journal:  Calcif Tissue Res       Date:  1978-08-18

6.  Bone remodelling in monoclonal gammopathies of uncertain significance, symptomatic and nonsymptomatic myeloma.

Authors:  M Laroche; M Attal; C Dromer
Journal:  Clin Rheumatol       Date:  1996-07       Impact factor: 2.980

Review 7.  RANKL/RANK/OPG: key therapeutic target in bone oncology.

Authors:  Kosei Ando; Kanji Mori; Francoise Rédini; Dominique Heymann
Journal:  Curr Drug Discov Technol       Date:  2008-09

8.  A minimally invasive surgical treatment possibility of osteolytic vertebral collapse in multiple myeloma.

Authors:  Stefano Astolfi; Laura Scaramuzzo; Carlo A Logroscino
Journal:  Eur Spine J       Date:  2009-05-13       Impact factor: 3.134

9.  Transcapillary exchange and retention of fluoride, strontium, EDTA, sucrose, and antipyrine in bone.

Authors:  G J Lemon; D R Davies; S P Hughes; J B Bassingthwaighte; P J Kelly
Journal:  Calcif Tissue Int       Date:  1980       Impact factor: 4.333

10.  In silico investigations of the anti-catabolic effects of pamidronate and denosumab on multiple myeloma-induced bone disease.

Authors:  Yan Wang; Bo Lin
Journal:  PLoS One       Date:  2012-09-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.